Biocept (BIOCQ) 10-Q 11 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 05, 2015
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Trading Symbol	BIOC
Entity Registrant Name	BIOCEPT INC
Entity Central Index Key	1,044,378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		18,703,546

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 16,523,975	$ 5,364,582
Accounts receivable	32,060	10,600
Inventories, net	253,864	188,728
Prepaid expenses and other current assets	589,573	338,721
Total current assets	17,399,472	5,902,631
Fixed assets, net	918,187	662,422
Total assets	18,317,659	6,565,053
Current liabilities:
Accounts payable	612,461	641,406
Accrued liabilities	884,579	699,903
Supplier financings		33,674
Current portion of equipment financings	117,096	55,800
Current portion of credit facility	1,403,742
Current portion of deferred rent	15,268
Total current liabilities	3,033,146	1,430,783
Non-current portion of equipment financings, net	251,232	68,801
Non-current portion of credit facility, net	3,389,402	4,731,322
Non-current portion of interest payable	105,265	54,537
Non-current portion of deferred rent	488,653	500,179
Total liabilities	$ 7,267,698	$ 6,785,622
Commitments and contingencies (see Note 10)
Shareholders’ equity/(deficit):
Common stock, $0.0001 par value, 40,000,000 authorized; 4,449,603 issued and outstanding at December 31, 2014; 18,646,732 issued and outstanding at June 30, 2015 (see Note 2).	$ 1,865	$ 445
Additional paid-in capital	157,170,951	138,066,008
Accumulated deficit	(146,122,855)	(138,287,022)
Total shareholders’ equity/(deficit)	11,049,961	(220,569)
Total liabilities and shareholders’ equity/(deficit)	$ 18,317,659	$ 6,565,053

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	40,000,000	40,000,000
Common stock, shares issued	18,646,732	4,449,603
Common stock, shares outstanding	18,646,732	4,449,603

Condensed Statements of Operati

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenues	$ 76,768	$ 19,245	$ 226,770	$ 47,520
Cost of revenues	985,219	359,364	1,842,192	1,017,679
Gross loss	(908,451)	(340,119)	(1,615,422)	(970,159)
Operating expenses
Research and development expenses	772,098	1,107,678	1,714,227	2,116,607
General and administrative expenses	1,359,226	1,032,855	2,651,275	2,909,767
Sales and marketing expenses	851,109	423,361	1,560,565	434,503
Loss from operations	(3,890,884)	(2,904,013)	(7,541,489)	(6,431,036)
Other income/(expense)
Interest expense, net	(169,036)	(94,111)	(318,476)	(1,488,555)
Change in fair value of warrant liability	(438)	2,084	(197)	(204,320)
Other income	25,608		25,608
Total other income/(expense)	(143,866)	(92,027)	(293,065)	(1,692,875)
Loss before income taxes	(4,034,750)	(2,996,040)	(7,834,554)	(8,123,911)
Income tax expense	(355)	(800)	(1,279)	(800)
Net loss & comprehensive loss	$ (4,035,105)	$ (2,996,840)	$ (7,835,833)	$ (8,124,711)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic	17,998,969	4,449,603	14,206,885	3,538,503
Diluted	17,998,969	4,449,603	14,206,885	3,538,503
Net loss per common share:
Basic	$ (0.22)	$ (0.67)	$ (0.55)	$ (2.30)
Diluted	$ (0.22)	$ (0.67)	$ (0.55)	$ (2.30)

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Cash Flows From Operating Activities
Net loss	$ (7,835,833)	$ (8,124,711)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	114,765	112,164
Inventory reserve	(14,801)	(8,545)
Stock-based compensation	676,895	1,185,164
Non-cash interest expense related to convertible debt, credit facility and other financing activities	68,412	1,396,413
Change in fair value of warrant liability	197	204,320
Increase/(decrease) in cash resulting from changes in:
Accounts receivable	(21,460)	(19,245)
Inventory	(50,335)	(41,775)
Prepaid expenses and other current assets	(313,963)	(544,972)
Accounts payable	(47,750)	(865,624)
Accrued liabilities	184,479	(1,256,892)
Non-current portion of interest payable	50,728	13,545
Deferred rent	3,742	22,158
Net cash used in operating activities	(7,184,924)	(7,928,000)
Cash Flows From Investing Activities
Purchases of fixed assets	(72,717)	(6,297)
Net cash used in investing activities	(72,717)	(6,297)
Cash Flows From Financing Activities
Net proceeds from issuance of common stock	8,825,058	17,390,240
Proceeds from exercise of common stock warrants	9,667,521
Payments on equipment financings	(41,871)
Payments on supplier and other third party financings	(33,674)	(156,558)
Payments on line of credit		(2,346,000)
Proceeds from borrowings on line of credit		365,000
Proceeds from issuance of convertible notes and warrants		175,000
Net proceeds from borrowings on credit facility and warrants		4,898,002
Net cash provided by financing activities	18,417,034	20,325,684
Net increase in Cash and Cash Equivalents	11,159,393	12,391,387
Cash and Cash Equivalents at Beginning of Period	5,364,582	69,178
Cash and Cash Equivalents at End of Period	16,523,975	12,460,565
Cash paid during the period for:
Interest	206,289	196,180
Taxes	$ 1,855	$ 800

Condensed Statements of Cash F6

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)	Feb. 10, 2014	Jun. 30, 2015	Jun. 30, 2014
Cancellation of insurance premiums amount, other			$ 44,559
Cancellation of insurance premiums partial amount received			10,955
Fair value of common stock warrants issued in conjunction with guarantees on additional borrowings			135,222
Overallotment issued to underwriter to purchase common stock, period	45 days	45 days
Purchase of common stock by underwriters to cover overallotments, number of shares	285,000
Purchase of common stock by underwriters to cover overallotments, per share	$ 9.30
Purchase of common stock by underwriters to cover overallotments, grant date fair value		$ 7,690,395
Warrants to purchase common stock, period	5 years	5 years
Issuance of warrants to purchase shares of common stock, grant date fair value		$ 1,627,396
Underwriter IPO costs	$ 279,760
Underwriter discount from initial public offering	1,330,000
Deferred offering costs classified to additional paid in capital	932,136
Warrants reclassified to additional paid-in capital	$ 2,500,000
Conversion price of notes	$ 10
Common shares issuable to underwriters under granted option		1,200,000
Common Shares issuable to underwriters under warrants granted		1,200,000
Common stock, par value		$ 0.0001
Offering costs recorded in prepaid expenses and other current assets reclassified to common stock issuance costs		$ 63,111
Purchases of fixed assets		38,993	$ 90,349
Fixed assets purchased under capital lease obligations		279,008
April 2014 Credit Facility [Member]
Issuance of warrants to purchase shares of common stock, grant date fair value		$ 233,107
Aegis Capital Corp
Purchase of common stock by underwriters to cover overallotments, grant date fair value	$ 202,143
Issuance of warrants to purchase shares of common stock	95,000
Exercise price of warrants	$ 12.50
Issuance of warrants to purchase shares of common stock, grant date fair value	$ 544,116
2008 Convertible Note [Member]
Debt, principal amount converted	$ 1,400,000
Conversion price of notes	$ 10
Convertible Bridge Notes And Line Of Credit [Member]
Exercise price of warrants	$ 10
Warrants reclassified to additional paid-in capital	$ 2,475,620
Warrants reclassified to additional paid-in capital	387,152
2013 Convertible Bridge Notes [Member]
Exercise price of warrants	$ 10
Debt, principal amount converted	$ 5,165,000
Accrued interest on convertible debt converted	$ 313,017
Conversion price of notes	$ 10
Convertible Note converted into preferred/common stock	548,803
Warrants reclassified to additional paid-in capital	258,249
Common Stock [Member] | 2008 Convertible Note [Member]
Convertible Note converted into preferred/common stock	163,399
Common Stock [Member] | 2013 Convertible Bridge Notes [Member]
Convertible Note converted into preferred/common stock	547,794
Accrued interest [Member] | 2008 Convertible Note [Member]
Accrued interest on convertible debt converted	$ 233,982
Accrued interest [Member] | 2013 Convertible Bridge Notes [Member]
Accrued interest on convertible debt converted	$ 300,000

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	1. Basis of Presentation Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (“SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles (“GAAP”) to be included in a full set of financial statements. The balance sheet at December 31, 2014 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2014, filed with the SEC with our Annual Report on Form 10-K on March 11, 2015 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Certain prior period amounts have been reclassified to conform to the current period presentation. The Company and Business Activities Biocept, Inc. (the “Company”) was founded in California in May 1997 and is a commercial-stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell (“CTC”) and circulating tumor DNA (“ctDNA”) assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures Cell Enrichment and Extraction (“CEE”) microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests (“LDTs”), under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013. Recent Accounting Pronouncements In May 2014, the Financial Standards Accounting Board (the “FASB”) issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In April 2015, the FASB issued authoritative guidance requiring debt issuance costs to be presented in the balance sheet as a direct deduction from the associated debt liability. This guidance is effective on a retrospective basis for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company early adopted this guidance on a retrospective basis for the interim reporting period ended March 31, 2015. A balance of $23,194 of such costs were reclassified from other non-current assets, net to non-current portion of credit facility, net in the Company’s balance sheet as of December 31, 2014. A total of $17,857 of such costs remain unamortized and recorded as an offset to non-current portion of credit facility, net in the Company’s unaudited condensed balance sheet at June 30, 2015.

Public Offerings

Public Offerings	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Public Offerings	2. Public Offerings Pursuant to an underwriting agreement dated February 4, 2014 between the Company and Aegis Capital Corp. (“Aegis”), as representative of the several underwriters named therein, an IPO of 1,900,000 shares of common stock at $10.00 per share was effected on February 5, 2014. The closing of the sale of these shares to the underwriters occurred on February 10, 2014. The Company received, after deducting underwriting discounts and additional costs paid to the underwriters, $17.4 million of net cash proceeds from the sale of these 1,900,000 shares. The total increase in capital as a result of the sale of these shares was $16.5 million after deducting $0.9 million of additional non-underwriter costs incurred that were netted against these proceeds under applicable accounting guidance. Additionally, the underwriters were granted a 45 day option from the closing date of the IPO to purchase up to 285,000 shares of common stock at $9.30 per share to cover overallotments with an estimated grant date fair value of $0.2 million, which was not exercised. In addition, designees of Aegis were issued warrants to buy (in the aggregate) up to 95,000 shares of common stock at $12.50 per share with a term of five years and an estimated grant date fair value of $0.5 million. On February 4, 2014, as contemplated by the registration statement covering the IPO, 69,421,047 shares of outstanding Series A Convertible Preferred Stock with a par value of $0.0001 per share were converted into 1,652,851 shares of common stock and the Company’s certificate of incorporation was amended to provide for an authorized capitalization of 40,000,000 shares of common stock and 5,000,000 shares of preferred stock. There were no shares of preferred stock issued or outstanding as of December 31, 2014 or June 30, 2015. In connection with the closing of the Company’s IPO on February 10, 2014, (i) the $1.4 million principal amount and $0.2 million of accrued interest related to the convertible note issued in 2008 were converted at $10.00 per share into a total of 163,399 shares of common stock, (ii) the $5.2 million principal amount and $0.3 million of accrued interest related to the convertible notes issued in 2013 were converted at $10.00 per share into a total of 547,794 shares of common stock, (iii) the exercise price of the warrants associated with the convertible notes issued in 2013 was fixed at $10.00 per share for an aggregate 258,249 shares of common stock, (iv) the exercise price of the warrants associated with the $2.6 million of collateral provided to secure the Company’s line of credit was fixed at $10.00 per share for an aggregate 128,903 shares of common stock, (v) 73,151 shares of common stock vested as settlement of certain restricted stock units (which were previously expressed in shares of preferred stock) and became issuable subsequent to the expiration of the 180 day lock-up period following the IPO, (vi) the Company’s Executive Chairman ceased to be an employee and continues to serve as non-executive Chairman, (vii) the number of shares of common stock covered by the Company’s 2013 Equity Incentive Plan increased by 800,000, (viii) all but 1,587 of the preferred warrants previously outstanding were canceled due to early termination clauses associated with the IPO, (ix) derivative warrant liabilities of $2.5 million associated with the aggregate of 387,152 common stock warrants related to the convertible notes issued in 2013 and line of credit were reclassified to additional paid-in capital when their underlying exercise price was fixed, (x) unamortized discounts of $1.0 million related to the warrants associated with the convertible notes issued in 2013 and line of credit were reclassified to interest expense, and (xi) offering costs associated with the IPO of $0.9 million were reclassified from prepaid expenses and other current assets to additional paid-in capital, while additional underwriter IPO costs and discounts of $0.3 million and $1.3 million, respectively, were netted against the proceeds from the IPO and are reflected as an offset to additional paid-in capital. Subsequent to December 31, 2013, the maximum amount of the Company’s line of credit was increased to approximately $2.6 million and common stock warrants were issued to four shareholders in conjunction with their guarantees on the Company’s additional borrowings under the line of credit. On February 10, 2014, the current outstanding balance under the line of credit of approximately $2.3 million plus accrued interest of $27,043 was paid in full using the net proceeds from the IPO. On February 13, 2014, the Compensation Committee of the Company’s Board of Directors approved payments of approximately $1.0 million for deferred salary obligations, including contractual interest, to current and former executive officers pursuant to previously existing agreements, which was fully disbursed by April 2014 using the net proceeds from the IPO. An additional $344,883 in deferred salary obligations and interest thereon was paid to former employees other than executive officers. Also on February 13, 2014, in connection with the closing of the IPO and pursuant to a director compensation policy adopted by the Company’s Board of Directors in 2013, the Company’s Board of Directors approved annual cash retainers to non-employee directors, and granted 238,500 stock options under the Company’s 2013 Equity Incentive Plan to non-employee directors. These option awards vest in equal annual installments over 3 years from the date of grant with a 10 year term, subject to continuing service requirements. Subsequently in February 2014, the Company’s Board of Directors approved grants of 54,298 stock options as a result of the closing of the IPO pursuant to the terms of underlying employment agreements. Included in the stock options granted pursuant to the terms of underlying employment agreements were 53,108 option awards granted to the Company’s non-executive Chairman, which vested fully on the date of grant. Under the terms of certain employment agreements with executive officers, the Company incurred additional cash compensation expense of $150,000 immediately, and $225,000 annually, upon the closing of its IPO. All payments required under these agreements as a result of the closing of the Company’s IPO on February 10, 2014 were subsequently made in February and March 2014, using the net proceeds from the IPO. During the year ended December 31, 2014, the Company repaid in full the remaining amounts outstanding of approximately $70,000 due for laboratory equipment under financing agreements with a supplier, which is a business owned by a member of the Company’s board of directors, using the net proceeds from the IPO. Pursuant to an underwriting agreement dated February 9, 2015 between the Company, Aegis and Feltl and Company, as underwriters named therein, a public offering of 8,000,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 8,000,000 shares of common stock was effected at a combined offering price of $1.25. The estimated grant date fair value of these warrants of $7.7 million was recorded as an offset to additional paid-in capital within common stock issuance upon the closing of this offering (see Note 4). Each of the members of the Company’s Board of Directors participated in this offering, purchasing an aggregate shares of the Company’s common stock and warrants to purchase up to an aggregate of shares of its common stock for a total purchase price of $ . All warrants sold in this offering

Liquidity

Liquidity	6 Months Ended
	Jun. 30, 2015
Cash And Cash Equivalents [Abstract]
Liquidity	3. Liquidity At December 31, 2014 and June 30, 2015, the Company had accumulated deficits of $138.3 million and $146.1 million, respectively. For the year and six month periods ended December 31, 2014 and June 30, 2015, the Company incurred net losses of $15.9 million and $7.8 million, respectively. The Company borrowed a total of $0.5 million during the year ended December 31, 2014 under note agreements with certain shareholders and a line of credit. In addition, the Company borrowed $5.0 million during the year ended December 31, 2014 under a credit facility entered into in April 2014. While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses in the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from clinical laboratory testing through contracted partners. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant net revenues to achieve and sustain income from operations. As of June 30, 2015, cash and cash equivalents totaled $16.5 million. On February 13, 2015, the Company received net cash proceeds of $9.1 million as a result of the closing of a follow-on public offering, before deducting $0.3 million of additional non-underwriting costs incurred. Subsequent to the closing of the follow-on public offering on February 13, 2015, additional cash proceeds of $9.7 million have been received from the exercise of warrants sold in such offering. Management believes that its cash resources should be sufficient to support currently forecasted operations through at least the next twelve months. Management expects that the Company may need additional financing in the future to execute on its current or future business strategies beyond the next twelve months. Until the Company can generate significant cash from operations, the Company expects to continue to fund its operations with the proceeds of offerings of the Company’s equity securities and debt. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all. In addition to assay revenues, such financing may be derived from one or more of the following types of transactions: debt, equity, product development, technology licensing or collaboration. In May 2015, the SEC declared effective a shelf registration statement filed by the Company. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million. As of June 30, 2015, the Company had not sold any securities under this shelf registration statement. The specific terms of future offerings, if any, under this shelf registration statement would be established at the time of such offerings.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurement	4. Fair Value Measurement The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, other than warrant liability, approximate their estimated fair values due to the short-term maturities of these financial instruments. The estimated fair value of the Company’s credit facility at June 30, 2015 approximated carrying value, which was determined using a discounted cash flow analysis. The analysis considered interest rates of instruments with similar maturity dates, which involved the use of significant unobservable Level 3 inputs. In connection with the closing of the Company’s public offering on February 13, 2015, warrants were issued to buy (in the aggregate) up to 8,000,000 shares of common stock with an estimated grant date fair value of $7,690,395, which was recorded as an offset to additional paid-in capital within common stock issuance costs. Also in connection with the closing of the Company’s follow-on public offering on February 13, 2015, the underwriters were granted a 45 day option from the closing date of the offering to purchase up to 1,200,000 additional shares of common stock at a price of $1.25 per share and/or additional warrants to purchase up to 1,200,000 shares of common stock at a price of $0.0001 per warrant, less underwriting discounts and commissions, to cover over-allotments, if any. The estimated aggregate grant date fair value of these over-allotment options and warrants of $1,627,396 was also recorded to common stock issuance costs as a component of additional paid-in capital. The fair values of these over-allotment options and all common stock warrants issued in this offering were estimated using Black-Scholes valuation models with the following assumptions: Over-allotment Options Warrants Stock price $ 1.41 $ 1.41 Exercise price $ 1.25 $ 1.56 Expected dividend yield 0.00 % 0.00 % Discount rate-bond equivalent yield 0.02 % 1.53 % Expected life (in years) 0.12 5.00 Expected volatility 168.1 % 90.0 %

Balance Sheet Details

Balance Sheet Details	6 Months Ended
	Jun. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Balance Sheet Details	5. Balance Sheet Details The following provides certain balance sheet details: December 31, June 30, 2014 2015 Fixed Assets Machinery and equipment $ 2,922,303 $ 2,973,832 Furniture and office equipment 209,844 209,844 Computer equipment and software 681,508 756,365 Leasehold improvements 506,328 510,398 Financed equipment 878,447 1,157,455 Construction in process 72,172 33,238 5,270,602 5,641,132 Less accumulated depreciation and amortization 4,608,180 4,722,945 Total fixed assets, net $ 662,422 $ 918,187 Accrued Liabilities Accrued interest $ 33,125 $ 33,125 Accrued payroll 82,241 268,217 Accrued vacation 276,574 310,837 Accrued bonuses 302,763 216,165 Accrued sales commissions — 32,352 Warrant liability 1,070 1,267 Other 4,130 22,616 Total accrued liabilities $ 699,903 $ 884,579

April 2014 Credit Facility

April 2014 Credit Facility	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
April 2014 Credit Facility	6. April 2014 Credit Facility On April 30, 2014, the Company received net cash proceeds of approximately $4,927,000 pursuant to the execution of its April 2014 Credit Facility with Oxford Finance LLC. A second term loan of up to a principal amount of $ million will be funded at the Company’s request prior to December 31, 2015, subject to the achievement of product and services revenues of at least $ million for the trailing six months, with such six-month period ending no later than November 30, 2015. Upon the entry into the April 2014 Credit Facility, the Company was required to pay the lenders a facility fee of $ in conjunction with the funding of the first term loan. Another $50, facility fee will be due and payable to the lenders on the funding date of the second term loan (if such date occurs). The April 2014 Credit Facility is secured by substantially all of the Company’s personal property other than its intellectual property. Each term loan under the April 2014 Credit Facility bears interest at an annual rate equal to the greater of (i) % or (ii) the sum of (a) the three-month U.S. LIBOR rate reported in the Wall Street Journal three business days prior to the funding date of the applicable term loan, plus (b) %, such rate to be fixed at the time of borrowing. The first term loan bears interest at an annual rate of %. The Company was required to make interest-only payments on the first term loan through August 1, 2015. If the Company requests and the lenders fund the second term loan, the Company is required to make interest-only payments on the second term loan through the seventh month following the funding date of the second term loan. All outstanding term loans under the April 2014 Credit Facility will begin amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lenders in consecutive monthly installments following such interest-only period. The first term loan under the April 2014 Credit Facility matures on July 1, 2018, and the second term loan matures on the first day of the 29th month following the end of the applicable interest-only period. Upon repayment of each term loan, the Company is also required to make a final payment to the lenders equal to % of the original principal amount of such term loan funded. At its option, the Company may prepay the outstanding principal balance of the term loans in whole but not in part, subject to a prepayment fee of % of the amount prepaid if the prepayment occurs prior to April 30, 2016, and % of any amount prepaid after April 30, 2016. The April 2014 Credit Facility includes affirmative and negative covenants applicable to the Company and any subsidiaries the Company creates in the future. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver certain financial reports and maintain insurance coverage. The negative covenants include, among others, restrictions on the Company’s transferring collateral, incurring additional indebtedness, engaging in mergers or acquisitions, paying dividends or making other distributions, making investments, creating liens, selling assets, and suffering a change in control, in each case subject to certain exceptions. The April 2014 Credit Facility also includes events of default, the occurrence and continuation of which provide Oxford Finance LLC, as collateral agent, with the right to exercise remedies against the Company and the collateral securing the term loans under the April 2014 Credit Facility, including foreclosure against the Company’s properties securing the April 2014 Credit Facility, including the Company’s cash. These events of default include, among other things, the Company’s failure to pay any amounts due under the April 2014 Credit Facility, a breach of covenants under the April 2014 Credit Facility, the Company’s insolvency, a material adverse change, the occurrence of any default under certain other indebtedness in an amount greater than $250,000, and a final judgment against the Company in an amount greater than $ . A warrant to purchase up to 52,966 shares of the Company’s common stock at an exercise price of $4.72 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. The estimated fair value of the warrant issued of $233,107 was recorded as a discount to outstanding debt as of the closing date. Additional warrants to purchase shares of the Company’s common stock will be issued upon execution of the second term loan under the April 2014 Credit Facility in an amount equal to 5.0% of the funded amount divided by the exercise price, which will be equal to the lower of (i) the closing price per share of the Company’s common stock on the NASDAQ on the date prior to the funding date of the second term loan or (ii) the ten-day average closing price per share prior to the funding date of the second term loan. The effective annual interest rate associated with the April 2014 Credit Facility was 10.81% at December 31, 2014 and 11.14% at June 30, 2015.

Stock-based Compensation

Stock-based Compensation	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-based Compensation	7. Stock-based Compensation Equity Incentive Plans On January 1, 2015, the number of shares of common stock covered by the Company’s 2013 Equity Incentive Plan automatically increased by 222,480 shares, or 5% of the number of common shares then outstanding, to a total of 1,426,051 shares. At the Company’s annual meeting of stockholders held on June 16, 2015, the stockholders approved the Company’s Amended and Restated 2013 Equity Incentive Plan (“2013 Plan”), which included (i) an increase in the number of shares of common stock authorized for issuance under the 2013 Plan by 1,500,000 shares, and (ii) a provision that shares available for grant under the Company’s 2007 Equity Incentive Plan (“2007 Plan”) become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. As of June 30, 2015, 3,012,147 shares were authorized for issuance under the 2013 Plan, 1,039,038 stock options and Restricted Stock Units (“RSUs”) had been issued and were outstanding, and 1,973,109 shares were available for grant. As of June 30, 2015, 102,710 stock options and RSUs had been issued under the 2007 Plan, of which 92,475 shares remain outstanding, and no shares were available for grant. Stock Options A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the six months ended June 30, 2015 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Vested and unvested expected to vest, December 31, 2014 901,882 $ 6.28 8.9 Outstanding at December 31, 2014 906,194 $ 6.29 9.0 Granted 22,000 $ 2.87 Exercised — — Cancelled/forfeited/expired (10,878 ) $ 4.09 Outstanding at June 30, 2015 917,316 $ 6.24 8.5 Vested and unvested expected to vest, June 30, 2015 912,608 $ 6.25 8.5 The intrinsic values of options outstanding and options vested and unvested expected to vest at June 30, 2015 were $1,320 and $1,229, respectively. The fair values of option awards granted during the six months ended June 30, 2015 were estimated using a Black-Scholes pricing model with the following assumptions: Stock and exercise prices $2.44 - $3.38 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.52% – 1.93% Expected life (in years) 5.98 – 6.08 Expected volatility 90.0% – 100.0% Using the assumptions described above, with stock and exercise prices being equal on date of grant, the weighted-average estimated fair value of options granted in the six months ended June 30, 2015 was $2.21 per share. Further information about the options outstanding and exercisable at June 30, 2015 is as follows: Weighted Weighted Average Average Total Shares Contractual Total Shares Exercise Price Outstanding Life (in years) Exercisable $ 2.72 59,500 9.5 — $ 4.33 113,901 8.5 41,673 $ 5.21 408,117 8.3 279,934 $ 7.50 43,000 8.7 13,437 $ 8.88 238,500 8.6 79,497 $ 9.11 54,298 8.6 54,298 917,316 468,839 The intrinsic value of options exercisable at June 30, 2015 was zero. Restricted Stock At June 30, 2015, there were 251,269 RSUs outstanding, of which 225,795 shares were vested and unvested expected to vest. The intrinsic values of RSUs outstanding and RSUs vested and unvested expected to vest at June 30, 2015 were $640,736 and $575,777, respectively. Stock-based Compensation Expense The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statement of operations and comprehensive loss during the periods presented: For the three months ended For the six months ended June 30, June 30, 2014 2015 2014 2015 Stock Options Cost of revenues $ - $ 17,674 $ - $ 33,810 Research and development expenses 44,023 24,505 114,057 44,925 General and administrative expenses 207,236 229,561 671,720 448,622 Sales and marketing expenses 17,715 31,089 18,929 62,101 Total expenses related to stock options 268,974 302,829 804,706 589,458 RSUs Research and development expenses 7,500 1,599 15,000 9,099 General and administrative expenses 13,750 38,402 365,458 78,338 Total stock-based compensation $ 290,224 $ 342,830 $ 1,185,164 $ 676,895 Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 5% and 0% - 4% per annum during the three and six months ended June 30, 2014 and 2015, respectively. As of June 30, 2015 total unrecognized stock-based compensation expense related to unvested stock option and RSU awards, adjusted for estimated forfeitures, was approximately $2,111,000 and $50,000, respectively, and is expected to be recognized over a weighted-average period of 2.3 years and 0.4 years, respectively.

Common Warrants Outstanding

Common Warrants Outstanding	6 Months Ended
	Jun. 30, 2015
Other Liabilities Disclosure [Abstract]
Common Warrants Outstanding	8. Common Warrants Outstanding A summary of equity-classified common stock warrant activity for the six months ended June 30, 2015 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2014 609,187 $ 9.93 3.8 Issued 9,200,000 $ 1.56 Exercised (6,197,129 ) $ 1.56 Expired (1,200,000 ) $ 1.56 Outstanding at June 30, 2015 2,412,058 $ 3.67 4.3 Further information about equity-classified common stock warrants outstanding and exercisable at June 30, 2015 is as follows: Weighted Weighted Average Average Total Shares Contractual Exercise Price Outstanding Life (in years) $ 1.56 1,802,871 4.6 $ 4.72 52,966 8.8 $ 10.00 461,221 2.6 $ 12.50 95,000 3.6 2,412,058 The intrinsic value of equity-classified common stock warrants outstanding and exercisable at June 30, 2015 was $1,784,842.

Net Loss per Common Share

Net Loss per Common Share	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Net Loss per Common Share	9. Net Loss per Common Share Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the three and six months ended June 30, 2014 and 2015, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Therefore, the weighted-average shares used to calculate both basic and diluted loss per share are the same. The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the three and six months ended June 30, 2014 2015 Preferred warrants outstanding (number of common stock equivalents) 1,587 1,587 Preferred share RSUs (number of common stock equivalents) 73,151 73,151 Common warrants outstanding 609,187 2,412,058 Common share RSUs 178,467 178,118 Common options outstanding 894,468 917,316 Total anti-dilutive common share equivalents 1,756,860 3,582,230

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	10. Commitments and Contingencies In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity. The Company’s former Vice President of Operations filed an administrative proceeding against the Company with the California Labor Commissioner in April 2013, seeking damages for alleged unpaid wages and penalties. A hearing was held on August 19, 2013 which resulted in a finding against the Company for approximately $65,000, of which $40,000 was paid during the year ended December 31, 2013 and $25,000 was accrued as of December 31, 2013. On February 25, 2014, the aforementioned administrative proceeding filed with the California Labor Commissioner by the Company’s former Vice President of Operations was settled in full following payment of the remaining $25,000 due.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	11. Related Party Transactions Each of the members of the Company’s Board of Directors participated in its public offering in February 2015, purchasing an aggregate of 142,000 shares of the Company’s common stock and warrants to purchase up to an aggregate of 142,000 shares of its common stock for a total purchase price of $177,500 (see Note 2). Pursuant to a sublease agreement dated March 30, 2015, the Company rented 9,849 square feet, plus free use of an additional area, of its San Diego facility to an entity affiliated with the Company’s non-executive Chairman for $12,804 per month, with a refundable security deposit of $12,804 due from the subtenant. The initial term of the sublease expired on July 31, 2015, and is subject to renewal on a month-to-month basis thereafter. A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc. (“Aegea”). On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement (the “Cross-License Agreement”) with Aegea. In May 2015, the Company received a reimbursement $25,259 from Aegea as reimbursement for shared patent costs under the Cross-License Agreement. The Company believes that these transactions were on terms at least as favorable to the Company as could have been obtained from unrelated third parties.

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission (“SEC”) instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by U.S. Generally Accepted Accounting Principles (“GAAP”) to be included in a full set of financial statements. The balance sheet at December 31, 2014 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2014, filed with the SEC with our Annual Report on Form 10-K on March 11, 2015 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Certain prior period amounts have been reclassified to conform to the current period presentation.
The Company and Business Activities	The Company and Business Activities Biocept, Inc. (the “Company”) was founded in California in May 1997 and is a commercial-stage cancer diagnostics company developing and commercializing proprietary circulating tumor cell (“CTC”) and circulating tumor DNA (“ctDNA”) assays utilizing a standard blood sample to improve the treatment that oncologists provide to their patients by providing better, more detailed information on the characteristics of their tumor. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures Cell Enrichment and Extraction (“CEE”) microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests (“LDTs”), under the CLIA regulations. In July 2013, the Company effected a reincorporation to Delaware by merging itself with and into Biocept, Inc., a Delaware corporation, which had been formed to be and was a wholly-owned subsidiary of the Company since July 23, 2013.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Standards Accounting Board (the “FASB”) issued authoritative guidance that requires entities to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. This proposed guidance has been deferred and would be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In June 2014, the FASB issued authoritative guidance requiring share-based payments with a performance target which affects vesting and that could be achieved after the requisite service period be treated as a performance condition. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. The Company does not expect adoption of this guidance to have a material impact on its financial statements or disclosures. In August 2014, the FASB issued authoritative guidance requiring management to evaluate whether there are conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. Certain additional financial statement disclosures are required if such conditions or events are identified. This guidance is effective for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company is currently in the process of evaluating the impact of the adoption of this guidance on its financial statements and disclosures. In April 2015, the FASB issued authoritative guidance requiring debt issuance costs to be presented in the balance sheet as a direct deduction from the associated debt liability. This guidance is effective on a retrospective basis for the annual reporting period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. The Company early adopted this guidance on a retrospective basis for the interim reporting period ended March 31, 2015. A balance of $23,194 of such costs were reclassified from other non-current assets, net to non-current portion of credit facility, net in the Company’s balance sheet as of December 31, 2014. A total of $17,857 of such costs remain unamortized and recorded as an offset to non-current portion of credit facility, net in the Company’s unaudited condensed balance sheet at June 30, 2015.
Fair Value Measurement	The Company uses a three-tier fair value hierarchy to prioritize the inputs used in the Company’s fair value measurements. These tiers include: Level 1, defined as observable inputs such as quoted prices in active markets for identical assets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions. The Company believes the carrying amount of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, other than warrant liability, approximate their estimated fair values due to the short-term maturities of these financial instruments. The estimated fair value of the Company’s credit facility at June 30, 2015 approximated carrying value, which was determined using a discounted cash flow analysis. The analysis considered interest rates of instruments with similar maturity dates, which involved the use of significant unobservable Level 3 inputs.

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2015
Over-allotment Option and Common Stock Warrants [Member]
Assumptions Used for Determining Fair Values of Over-allotment Option and Common Stock Warrants	The fair values of these over-allotment options and all common stock warrants issued in this offering were estimated using Black-Scholes valuation models with the following assumptions: Over-allotment Options Warrants Stock price $ 1.41 $ 1.41 Exercise price $ 1.25 $ 1.56 Expected dividend yield 0.00 % 0.00 % Discount rate-bond equivalent yield 0.02 % 1.53 % Expected life (in years) 0.12 5.00 Expected volatility 168.1 % 90.0 %

Balance Sheet Details (Tables)

Balance Sheet Details (Tables)	6 Months Ended
	Jun. 30, 2015
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Fixed Assets and Accrued Liabilities	The following provides certain balance sheet details: December 31, June 30, 2014 2015 Fixed Assets Machinery and equipment $ 2,922,303 $ 2,973,832 Furniture and office equipment 209,844 209,844 Computer equipment and software 681,508 756,365 Leasehold improvements 506,328 510,398 Financed equipment 878,447 1,157,455 Construction in process 72,172 33,238 5,270,602 5,641,132 Less accumulated depreciation and amortization 4,608,180 4,722,945 Total fixed assets, net $ 662,422 $ 918,187 Accrued Liabilities Accrued interest $ 33,125 $ 33,125 Accrued payroll 82,241 268,217 Accrued vacation 276,574 310,837 Accrued bonuses 302,763 216,165 Accrued sales commissions — 32,352 Warrant liability 1,070 1,267 Other 4,130 22,616 Total accrued liabilities $ 699,903 $ 884,579

Stock-based Compensation (Table

Stock-based Compensation (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity for Option Awards Granted	A summary of stock option activity for option awards granted under the 2013 Plan and 2007 Plan for the six months ended June 30, 2015 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Vested and unvested expected to vest, December 31, 2014 901,882 $ 6.28 8.9 Outstanding at December 31, 2014 906,194 $ 6.29 9.0 Granted 22,000 $ 2.87 Exercised — — Cancelled/forfeited/expired (10,878 ) $ 4.09 Outstanding at June 30, 2015 917,316 $ 6.24 8.5 Vested and unvested expected to vest, June 30, 2015 912,608 $ 6.25 8.5
Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model	The fair values of option awards granted during the six months ended June 30, 2015 were estimated using a Black-Scholes pricing model with the following assumptions: Stock and exercise prices $2.44 - $3.38 Expected dividend yield 0.00 % Discount rate-bond equivalent yield 1.52% – 1.93% Expected life (in years) 5.98 – 6.08 Expected volatility 90.0% – 100.0%
Schedule of Information about Options Outstanding and Exercisable	Further information about the options outstanding and exercisable at June 30, 2015 is as follows: Weighted Weighted Average Average Total Shares Contractual Total Shares Exercise Price Outstanding Life (in years) Exercisable $ 2.72 59,500 9.5 — $ 4.33 113,901 8.5 41,673 $ 5.21 408,117 8.3 279,934 $ 7.50 43,000 8.7 13,437 $ 8.88 238,500 8.6 79,497 $ 9.11 54,298 8.6 54,298 917,316 468,839
Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss	The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statement of operations and comprehensive loss during the periods presented: For the three months ended For the six months ended June 30, June 30, 2014 2015 2014 2015 Stock Options Cost of revenues $ - $ 17,674 $ - $ 33,810 Research and development expenses 44,023 24,505 114,057 44,925 General and administrative expenses 207,236 229,561 671,720 448,622 Sales and marketing expenses 17,715 31,089 18,929 62,101 Total expenses related to stock options 268,974 302,829 804,706 589,458 RSUs Research and development expenses 7,500 1,599 15,000 9,099 General and administrative expenses 13,750 38,402 365,458 78,338 Total stock-based compensation $ 290,224 $ 342,830 $ 1,185,164 $ 676,895

Common Warrants Outstanding (Ta

Common Warrants Outstanding (Tables)	6 Months Ended
	Jun. 30, 2015
Warrants And Rights Note Disclosure [Abstract]
Summary of Equity-Classified Common Stock Warrant Activity	A summary of equity-classified common stock warrant activity for the six months ended June 30, 2015 is as follows: Average Weighted Remaining Number of Average Exercise Contractual Shares Price Per Share Term in Years Outstanding at December 31, 2014 609,187 $ 9.93 3.8 Issued 9,200,000 $ 1.56 Exercised (6,197,129 ) $ 1.56 Expired (1,200,000 ) $ 1.56 Outstanding at June 30, 2015 2,412,058 $ 3.67 4.3
Schedule of Equity-Classified Common Stock Warrants Outstanding And Exercisable	Further information about equity-classified common stock warrants outstanding and exercisable at June 30, 2015 is as follows: Weighted Weighted Average Average Total Shares Contractual Exercise Price Outstanding Life (in years) $ 1.56 1,802,871 4.6 $ 4.72 52,966 8.8 $ 10.00 461,221 2.6 $ 12.50 95,000 3.6 2,412,058

Net Loss per Common Share (Tabl

Net Loss per Common Share (Tables)	6 Months Ended
	Jun. 30, 2015
Earnings Per Share [Abstract]
Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares	The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive: For the three and six months ended June 30, 2014 2015 Preferred warrants outstanding (number of common stock equivalents) 1,587 1,587 Preferred share RSUs (number of common stock equivalents) 73,151 73,151 Common warrants outstanding 609,187 2,412,058 Common share RSUs 178,467 178,118 Common options outstanding 894,468 917,316 Total anti-dilutive common share equivalents 1,756,860 3,582,230

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) - Jun. 30, 2015 - USD ($)	Total
Accounting Policies [Abstract]
Prior period reclassification adjustment amount related to other non current assets	$ 23,194
Unamortized debt issuance costs	$ 17,857

Public Offerings - Additional I

Public Offerings - Additional Information (Detail) - USD ($)	Feb. 13, 2015	Feb. 09, 2015	Feb. 21, 2014	Feb. 13, 2014	Feb. 10, 2014	Feb. 04, 2014	Apr. 30, 2014	Mar. 31, 2014	Feb. 28, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Class Of Stock [Line Items]
Public offering, number of shares issued						1,900,000
Initial public offering, price per share						$ 10
Net cash proceeds from issue of initial public offering after deducting underwriting discounts and additional costs					$ 17,400,000
Increase in capital shares value		$ 8,800,000
Additional costs incurred prior to, and associated with IPO, beginning of period	$ 200,000				$ 900,000
Purchase of common stock by underwriters to cover overallotments, number of shares	1,200,000				285,000
Purchase of common stock by underwriters to cover overallotments, per share	$ 1.25				$ 9.30
Issuance of warrants to purchase shares of common stock	1,200,000
Exercise price of warrants	$ 1.56
Overallotment issued to underwriter to purchase common stock, period		45 days			45 days					45 days
Purchase of common stock by underwriters to cover overallotments, grant date fair value		$ 7,690,395								$ 7,690,395
Warrants to purchase common stock, period	5 years				5 years					5 years
Issuance of warrants to purchase shares of common stock, grant date fair value		1,627,396								$ 1,627,396
Series A Preferred Stock, shares converted to common stock						69,421,047
Preferred stock, par value						$ 0.0001
Common stock, shares issued upon conversion of Series A Preferred Stock						1,652,851
Common stock, shares authorized						40,000,000				40,000,000		40,000,000
Preferred stock, shares authorized						5,000,000
Preferred stock, shares outstanding										0		0
Preferred stock, shares issued										0		0
Conversion price of notes					$ 10
Shares of common stock vested as settlement of certain restricted stock units					73,151
Lock-up period					180 days
Preferred warrants outstanding after cancellation of warrants due to early termination clauses					1,587
Warrants reclassified to additional paid-in capital					$ 2,500,000
Unamortized discounts related to warrants					1,000,000
Underwriter IPO costs					279,760
Underwriter IPO discounts					1,300,000
Offering costs associated with IPO					900,000
Maximum amount of line of credit								$ 2,600,000
Line of credit, outstanding balance repaid					2,300,000						$ 2,346,000
Line of credit, accrued interest paid					$ 27,043
Payment of deferred salary obligations							$ 1,000,000	$ 225,000	$ 150,000
Stock options granted										22,000
Repayment of laboratory equipment dues to supplier												$ 70,000
Proceeds from issuance of common stock	$ 177,500									$ 8,825,058	$ 17,390,240
Net proceeds from issuance of common stock	$ 9,100,000
Common stock, par value	$ 0.0001									$ 0.0001		$ 0.0001
Underwriter cost										$ 200,000
Underwriting discounts										700,000
Non-underwriter costs	$ 300,000									300,000
Proceeds from exercise of common stock warrants	$ 9,700,000	$ 9,700,000								9,667,521
Aggregate increase in capital from public offerings										$ 18,500,000
Employee [Member]
Class Of Stock [Line Items]
Payment of additional deferred salary obligations							$ 344,883
Director
Class Of Stock [Line Items]
Public offering, number of shares issued	142,000
Issuance of warrants to purchase shares of common stock		142,000
2013 Equity Incentive Plan [Member]
Class Of Stock [Line Items]
Common stock, shares authorized												1,426,051
Increase in number of shares of common stock covered by plan					800,000
Stock options granted			54,298
Option awards vesting period				3 years
Option awards expiration period				10 years
2013 Equity Incentive Plan [Member] | Director
Class Of Stock [Line Items]
Stock options granted				238,500
2013 Equity Incentive Plan [Member] | Non Executive Chairman [Member]
Class Of Stock [Line Items]
Stock options granted				53,108
2008 Convertible Note [Member]
Class Of Stock [Line Items]
Debt, principal amount converted					$ 1,400,000
Conversion price of notes					$ 10
2013 Convertible Bridge Notes [Member]
Class Of Stock [Line Items]
Exercise price of warrants					$ 10
Debt, principal amount converted					$ 5,165,000
Conversion price of notes					$ 10
Convertible Note converted into preferred/common stock					548,803
Accrued interest on convertible debt converted					$ 313,017
Warrants reclassified to additional paid-in capital					258,249
Line of Credit [Member]
Class Of Stock [Line Items]
Exercise price of warrants					$ 10
Warrants reclassified to additional paid-in capital					128,903
Collateral amount provided to secure Line of Credit					$ 2,600,000
Convertible Bridge Notes And Line Of Credit [Member]
Class Of Stock [Line Items]
Exercise price of warrants					$ 10
Warrants reclassified to additional paid-in capital					387,152
Warrants reclassified to additional paid-in capital					$ 2,475,620
Accrued interest [Member] | 2008 Convertible Note [Member]
Class Of Stock [Line Items]
Accrued interest on convertible debt converted					233,982
Accrued interest [Member] | 2013 Convertible Bridge Notes [Member]
Class Of Stock [Line Items]
Accrued interest on convertible debt converted					$ 300,000
Aegis Capital Corp
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock	8,000,000				95,000
Exercise price of warrants					$ 12.50
Purchase of common stock by underwriters to cover overallotments, grant date fair value					$ 202,143
Issuance of warrants to purchase shares of common stock, grant date fair value					544,116
Aegis and Feltl [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued	8,000,000
Issuance of warrants to purchase shares of common stock		8,000,000
Offering, price per share		$ 1.25
Common Stock [Member]
Class Of Stock [Line Items]
Increase in capital shares value					$ 16,500,000
Common Stock [Member] | 2008 Convertible Note [Member]
Class Of Stock [Line Items]
Convertible Note converted into preferred/common stock					163,399
Common Stock [Member] | 2013 Convertible Bridge Notes [Member]
Class Of Stock [Line Items]
Convertible Note converted into preferred/common stock					547,794

Liquidity - Additional Informat

Liquidity - Additional Information (Detail) - USD ($)	Feb. 13, 2015	Feb. 09, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	May. 31, 2015	Dec. 31, 2013
Liquidity And Managements Plans [Line Items]
Accumulated deficit			$ (146,122,855)		$ (146,122,855)		$ (138,287,022)
Net loss			(4,035,105)	$ (2,996,840)	(7,835,833)	$ (8,124,711)	(15,900,000)
Cash and cash equivalents			16,523,975	$ 12,460,565	16,523,975	$ 12,460,565	5,364,582		$ 69,178
Net proceeds from issuance of common stock	$ 9,100,000
Proceeds from exercise of common stock warrants	9,700,000	$ 9,700,000			9,667,521
Non-underwriter costs	$ 300,000		$ 300,000		$ 300,000
Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Securities issued during period								0
Maximum [Member] | Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Aggregate initial offering price								$ 50,000,000
Note Agreements with Certain Shareholders and Line of Credit [Member]
Liquidity And Managements Plans [Line Items]
Debt instrument carrying amount							500,000
April 2014 Credit Facility [Member]
Liquidity And Managements Plans [Line Items]
Credit facility, net							$ 5,000,000

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Detail) - USD ($)	Feb. 09, 2015	Feb. 10, 2014	Jun. 30, 2015	Feb. 13, 2015	Dec. 31, 2014
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of warrants to purchase shares of common stock				1,200,000
Issuance of warrants to purchase shares of common stock, grant date fair value	$ 1,627,396		$ 1,627,396
Overallotment issued to underwriter to purchase common stock, period	45 days	45 days	45 days
Purchase of common stock by underwriters to cover overallotments, number of shares		285,000		1,200,000
Purchase of common stock by underwriters to cover overallotments, per share		$ 9.30		$ 1.25
Common stock, par value			$ 0.0001	$ 0.0001	$ 0.0001
Purchase of common stock by underwriters to cover overallotments, grant date fair value	$ 7,690,395		$ 7,690,395
Aegis Capital Corp
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of warrants to purchase shares of common stock		95,000		8,000,000
Issuance of warrants to purchase shares of common stock, grant date fair value		$ 544,116
Purchase of common stock by underwriters to cover overallotments, grant date fair value		$ 202,143

Fair Value Measurement - Assump

Fair Value Measurement - Assumptions Used for Determining Fair Values of Over-allotment Option and Common Stock Warrants (Detail) - Jun. 30, 2015 - $ / shares	Total
Over-allotment Options [Member]
Fair Value Assumption Black Scholes Valuation Models [Line Items]
Stock price	$ 1.41
Exercise price	$ 1.25
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	0.02%
Expected life (in years)	1 month 13 days
Expected volatility	168.10%
Warrants [Member]
Fair Value Assumption Black Scholes Valuation Models [Line Items]
Stock price	$ 1.41
Exercise price	$ 1.56
Expected dividend yield	0.00%
Discount rate-bond equivalent yield	1.53%
Expected life (in years)	5 years
Expected volatility	90.00%

Balance Sheet Details - Schedul

Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Fixed Assets
Machinery and equipment	$ 2,973,832	$ 2,922,303
Furniture and office equipment	209,844	209,844
Computer equipment and software	756,365	681,508
Leasehold improvements	510,398	506,328
Financed equipment	1,157,455	878,447
Construction in process	33,238	72,172
Total fixed assets, gross	5,641,132	5,270,602
Less accumulated depreciation and amortization	4,722,945	4,608,180
Total fixed assets, net	918,187	662,422
Accrued Liabilities
Accrued interest	33,125	33,125
Accrued payroll	268,217	82,241
Accrued vacation	310,837	276,574
Accrued bonuses	216,165	302,763
Accrued sales commissions	32,352
Warrant liability	1,267	1,070
Other	22,616	4,130
Total accrued liabilities	$ 884,579	$ 699,903

April 2014 Credit Facility - Ad

April 2014 Credit Facility - Additional Information (Detail) - USD ($)	Feb. 13, 2015	Feb. 09, 2015	Apr. 30, 2014	Feb. 10, 2014	Jun. 30, 2015	Dec. 31, 2014	Mar. 31, 2014
Line of Credit Facility [Line Items]
Maximum amount of line of credit							$ 2,600,000
Exercise price of warrants	$ 1.56
Warrant term	5 years			5 years	5 years
Issuance of warrants to purchase shares of common stock, grant date fair value		$ 1,627,396			$ 1,627,396
Oxford Finance LLC [Member] | Common Stock [Member]
Line of Credit Facility [Line Items]
Warrant issued to lender			52,966
Exercise price of warrants			$ 4.72
Warrant term			10 years
Oxford Finance LLC [Member] | Minimum [Member]
Line of Credit Facility [Line Items]
Debt Default limit amount			$ 250,000
Debt default final judgment amount			250,000
Oxford Finance LLC [Member] | First Term Loan [Member]
Line of Credit Facility [Line Items]
Net cash proceeds on term loan			4,927,000
Line Of Credit Facility Fees Amount Payable			$ 50,000
Line of Credit Facility, Interest Rate During Period			7.95%
Percentage of final interest payment due at maturity			5.50%
Issuance of warrants to purchase shares of common stock, grant date fair value						$ 233,107
Effective annual interest rate					11.14%	10.81%
Additional warrants issued percentage					5.00%
Oxford Finance LLC [Member] | Second Term Loan [Member]
Line of Credit Facility [Line Items]
Maximum amount of line of credit			$ 5,000,000
Debt Instrument covenant requirement revenue			9,000,000
Line Of Credit Facility Fees Amount Payable			$ 50,000
Oxford Finance LLC [Member] | One Year [Member]
Line of Credit Facility [Line Items]
Term Loan prepayment fee percentage			2.00%
Oxford Finance LLC [Member] | Two Years [Member]
Line of Credit Facility [Line Items]
Term Loan prepayment fee percentage			1.00%
Oxford Finance LLC [Member] | Scenario One
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate During Period			7.95%
Oxford Finance LLC [Member] | Scenario Two
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate During Period			7.71%

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Detail) - USD ($)	Jun. 16, 2015	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Feb. 04, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Common stock, shares authorized		40,000,000		40,000,000		40,000,000	40,000,000
Total Shares Outstanding		917,316		917,316		906,194
Number of Shares, Vested and unvested expected to vest		912,608		912,608		901,882
Unrecognized stock-based compensation expense, stock options		$ 2,111,000		$ 2,111,000
Unrecognized stock-based compensation expense, RSU awards		$ 50,000		$ 50,000
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate		0.00%	0.00%	0.00%	0.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate		4.00%	5.00%	4.00%	5.00%
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options outstanding		$ 1,320		$ 1,320
Intrinsic value of options vested and unvested expected to vest		1,229		$ 1,229
Option awards assumptions, method used				Black-Scholes pricing model
Weighted-average estimated fair value of options granted				$ 2.21
Intrinsic value of options exercisable		$ 0		$ 0
Unrecognized stock-based compensation expense, weighted-average recognition period				2 years 3 months 18 days
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Shares Outstanding		251,269		251,269
Intrinsic value of options vested and unvested expected to vest		$ 575,777		$ 575,777
Number of Shares, Vested and unvested expected to vest		225,795		225,795
Intrinsic value shares, RSUs outstanding		$ 640,736		$ 640,736
Unrecognized stock-based compensation expense, weighted-average recognition period				4 months 24 days
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Increase Common stock shares covered	1,500,000					222,480
Percentage of outstanding common stock						5.00%
Common stock, shares authorized						1,426,051
Shares available for grant		1,973,109		1,973,109
Stock options and RSUs authorized		3,012,147		3,012,147
Stock options and RSUs issued				1,039,038
Total Shares Outstanding		1,039,038		1,039,038
Two Thousand Seven Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares available for grant		0		0
Stock options and RSUs issued				102,710
Total Shares Outstanding		92,475		92,475

Stock-based Compensation - Summ

Stock-based Compensation - Summary of Stock Option Activity for Option Awards Granted (Detail) - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares, Vested and unvested expected to vest, Beginning Balance	901,882
Number of Shares Outstanding, Beginning Balance	906,194
Number of Shares, Granted	22,000
Number of Shares, Cancelled/forfeited/expired	(10,878)
Number of Shares Outstanding, Ending Balance	917,316	906,194
Number of Shares, Vested and unvested expected to vest, Ending Balance	912,608	901,882
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Beginning Balance	$ 6.28
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	6.29
Weighted Average Exercise Price Per Share, Granted	2.87
Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired	4.09
Weighted Average Exercise Price Per Share, Outstanding, Ending balance	6.24	$ 6.29
Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance	$ 6.25	$ 6.28
Average Remaining Contractual Term in Years, Vested and unvested expected to vest	8 years 6 months	8 years 10 months 24 days
Average Remaining Contractual Term in Years, Outstanding	8 years 6 months	9 years

Stock-based Compensation - Assu

Stock-based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail) - Jun. 30, 2015 - $ / shares	Total
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 2.44
Discount rate-bond equivalent yield	1.52%
Expected life (in years)	5 years 11 months 23 days
Expected volatility	90.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 3.38
Discount rate-bond equivalent yield	1.93%
Expected life (in years)	6 years 29 days
Expected volatility	100.00%

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Information about Options Outstanding and Exercisable (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total Shares Outstanding	917,316	906,194
Total Shares Exercisable	468,839
Weighted Average Exercise Price 2.72 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price	$ 2.72
Total Shares Outstanding	59,500
Weighted Average Contractual Life (in years)	9 years 6 months
Weighted Average Exercise Price 4.33 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price	$ 4.33
Total Shares Outstanding	113,901
Weighted Average Contractual Life (in years)	8 years 6 months
Total Shares Exercisable	41,673
Weighted Average Exercise Price 5.22 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price	$ 5.21
Total Shares Outstanding	408,117
Weighted Average Contractual Life (in years)	8 years 3 months 18 days
Total Shares Exercisable	279,934
Weighted Average Exercise Price 7.50 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price	$ 7.50
Total Shares Outstanding	43,000
Weighted Average Contractual Life (in years)	8 years 8 months 12 days
Total Shares Exercisable	13,437
Weighted Average Exercise Price 8.88 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price	$ 8.88
Total Shares Outstanding	238,500
Weighted Average Contractual Life (in years)	8 years 7 months 6 days
Total Shares Exercisable	79,497
Weighted Average Exercise Price 9.11 [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Weighted Average Exercise Price	$ 9.11
Total Shares Outstanding	54,298
Weighted Average Contractual Life (in years)	8 years 7 months 6 days
Total Shares Exercisable	54,298

Stock-based Compensation - Effe

Stock-based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 302,829	$ 268,974	$ 589,458	$ 804,706
Stock Options [Member] | Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	17,674		33,810
Stock Options [Member] | Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	24,505	44,023	44,925	114,057
Stock Options [Member] | General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	229,561	207,236	448,622	671,720
Stock Options [Member] | Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	31,089	17,715	62,101	18,929
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	342,830	290,224	676,895	1,185,164
RSUs [Member] | Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	1,599	7,500	9,099	15,000
RSUs [Member] | General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 38,402	$ 13,750	$ 78,338	$ 365,458

Common Warrants Outstanding - S

Common Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) - Common Stock Warrant [Member] - $ / shares	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Class Of Warrant Or Right [Line Items]
Number of Shares, Outstanding, Beginning Balance	609,187
Number of Shares, Issued	9,200,000
Number of Shares, Exercised	(6,197,129)
Number of Shares, Expired	(1,200,000)
Number of Shares, Outstanding, Ending Balance	2,412,058	609,187
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 9.93
Weighted Average Exercise Price Per Share, Issued	1.56
Weighted Average Exercise Price Per Share, Exercised	1.56
Weighted Average Exercise Price Per Share, Expired	1.56
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	$ 3.67	$ 9.93
Average Remaining Contractual Term (in years)	4 years 3 months 18 days	3 years 9 months 18 days

Common Warrants Outstanding - E

Common Warrants Outstanding - Equity-Classified Common Stock Warrants Outstanding And Exercisable (Detail) - $ / shares	6 Months Ended
	Jun. 30, 2015	Feb. 13, 2015	Feb. 10, 2014
Class Of Warrant Or Right [Line Items]
Exercise price of warrants		$ 1.56
Total Shares Outstanding			1,587
Common Stock Warrant [Member]
Class Of Warrant Or Right [Line Items]
Total Shares Outstanding	2,412,058
Common Stock Warrant [Member] | Weighted Average Exercise Price 1.56 [Member]
Class Of Warrant Or Right [Line Items]
Exercise price of warrants	$ 1.56
Total Shares Outstanding	1,802,871
Weighted Average Contractual Life (in years)	4 years 7 months 6 days
Common Stock Warrant [Member] | Weighted Average Exercise Price 4.72 [Member]
Class Of Warrant Or Right [Line Items]
Exercise price of warrants	$ 4.72
Total Shares Outstanding	52,966
Weighted Average Contractual Life (in years)	8 years 9 months 18 days
Common Stock Warrant [Member] | Weighted Average Exercise Price 10.00 [Member]
Class Of Warrant Or Right [Line Items]
Exercise price of warrants	$ 10
Total Shares Outstanding	461,221
Weighted Average Contractual Life (in years)	2 years 7 months 6 days
Common Stock Warrant [Member] | Weighted Average Exercise Price 12.50 [Member]
Class Of Warrant Or Right [Line Items]
Exercise price of warrants	$ 12.50
Total Shares Outstanding	95,000
Weighted Average Contractual Life (in years)	3 years 7 months 6 days

Common Warrants Outstanding - A

Common Warrants Outstanding - Additional Information (Detail)	Jun. 30, 2015USD ($)
Warrants And Rights Note Disclosure [Abstract]
Common stock warrants exercisable, intrinsic value	$ 1,784,842
Common stock warrants outstanding, intrinsic value	$ 1,784,842

Net Loss per Common Share - Sch

Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) - shares	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	3,582,230	1,756,860
Warrants Outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	2,412,058	609,187
Preferred Warrants Outstanding [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	1,587	1,587
Preferred Share RSUs [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	73,151	73,151
Common Share RSUs [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	178,118	178,467
Common Options Outstanding [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	917,316	894,468

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	Feb. 25, 2014	Dec. 31, 2013	Aug. 19, 2013
Commitments And Contingencies Disclosure [Abstract]
Alleged unpaid wages and penalties			$ 65,000
Alleged unpaid wages and penalties, paid	$ 25,000	$ 40,000
Alleged unpaid wages and penalties, accrued		$ 25,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	May. 31, 2015USD ($)	Feb. 13, 2015USD ($)shares	Feb. 04, 2014shares	Jun. 30, 2015USD ($)ft²	Jun. 30, 2014USD ($)	Feb. 09, 2015shares
Related Party Transaction [Line Items]
Initial public offering, number of shares issued | shares			1,900,000
Issuance of warrants to purchase shares of common stock | shares		1,200,000
Proceeds from issuance of common stock		$ 177,500		$ 8,825,058	$ 17,390,240
Director
Related Party Transaction [Line Items]
Initial public offering, number of shares issued | shares		142,000
Issuance of warrants to purchase shares of common stock | shares						142,000
Proceeds from issuance of common stock		$ 177,500
Nonexecutive [Member]
Related Party Transaction [Line Items]
Lease agreement date of commencement				Mar. 30, 2015
Leased facility, rent expense per month				$ 12,804
Lease facility, refundable security deposit amount				$ 12,804
Lease expiration date				Jul. 31, 2015
Nonexecutive [Member] | San Diego California Facility [Member]
Related Party Transaction [Line Items]
Leased facility, expansion of original premises | ft²				9,849
Aegea Biotechnologies, Inc [Member]
Related Party Transaction [Line Items]
Reimbursement for shared patent costs	$ 25,259